JP2001072601A - Infection preventing and treating agent derived from grifola frondosa - Google Patents
Infection preventing and treating agent derived from grifola frondosaInfo
- Publication number
- JP2001072601A JP2001072601A JP24919299A JP24919299A JP2001072601A JP 2001072601 A JP2001072601 A JP 2001072601A JP 24919299 A JP24919299 A JP 24919299A JP 24919299 A JP24919299 A JP 24919299A JP 2001072601 A JP2001072601 A JP 2001072601A
- Authority
- JP
- Japan
- Prior art keywords
- maitake
- extract
- dried
- infection
- grifola frondosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は生体にとって有害な
病原微生物に対する感染防御・治療剤に関する。The present invention relates to an agent for protecting and treating infections against pathogenic microorganisms harmful to living organisms.
【０００２】[0002]
【従来の技術】人類は今世紀半ばまで病原微生物による
感染症に悩まされてきた。しかしサルファ剤や抗生物質
等化学療法剤が開発され、病原微生物、特に細菌類によ
る感染症は一応征服されたかのごとく見えた。しかし抗
生物質、化学療法剤に対する耐性菌の出現、それに加え
自然環境の破壊、都市の過密、航空機などの発達等生活
環境の変化により、新興・再興感染症の発生が見られる
ようになり再び感染症に対する対策が大きな課題となっ
てきている。BACKGROUND OF THE INVENTION Humans have suffered from infectious diseases caused by pathogenic microorganisms until the middle of this century. However, chemotherapeutic agents such as sulfa drugs and antibiotics were developed, and infections caused by pathogenic microorganisms, especially bacteria, seemed to be conquered. However, due to the emergence of resistant bacteria to antibiotics and chemotherapeutic agents, as well as changes in the living environment such as the destruction of the natural environment, overcrowding of cities, development of aircraft, etc. Countermeasures against illness have become a major issue.
【０００３】病原微生物は、強力で新しい作用機序の抗
生物質が出現してもやがて耐性を獲得してしまう。例え
ばMRSA（メチシリン耐性黄色ブドウ球菌）出現後すでに
VRE（バンコマイシン耐性腸球菌）など出現し、老人や
癌患者などの日和見感染、院内感染等深刻な問題を投げ
かけている。[0003] Pathogenic microorganisms eventually acquire resistance even with the emergence of antibiotics with a powerful new mechanism of action. For example, after the emergence of MRSA (methicillin-resistant Staphylococcus aureus)
The emergence of VRE (vancomycin-resistant enterococci) has caused serious problems such as opportunistic infections and hospital-acquired infections in elderly people and cancer patients.
【０００４】[0004]
【発明が解決しようとする課題】本発明は、生体防御力
を高め、感染症に対する防御あるいは治療に有効な感染
防御・治療剤の開発を課題とする。SUMMARY OF THE INVENTION An object of the present invention is to develop an agent for preventing and treating infection which is effective for protecting or treating infectious diseases by enhancing the body defense.
【０００５】[0005]
【課題を解決するための手段】本発明者は、上記課題を
解決すべく鋭意努力し、日常食品として摂取されている
物、すなわち生体適合性に優れた材料の中に感染防御作
用のあるものはないか広範囲に検索した結果、担子菌、
ヒダナシタケ目、タコウキン科のキノコであるマイタケ
に、病原微生物に対する優れた感染防御作用があること
を見出し本発明を完成した。Means for Solving the Problems The present inventor has made intensive efforts to solve the above-mentioned problems, and has a substance which is ingested as a daily food, that is, a material having an excellent biocompatibility and which has a protective action against infection. Searched extensively for basidiomycetes,
The present inventors have found that Maitake mushrooms, which are mushrooms belonging to the order Amanita and the octopus, have an excellent protective action against pathogenic microorganisms, and completed the present invention.
【０００６】即ち本発明は、（1）マイタケ抽出物若し
くは/及び乾燥マイタケ粉末を含有することを特徴とす
る感染防御・治療剤、（2）マイタケ抽出物が、生マイ
タケ、乾燥マイタケ若しくは/及び乾燥マイタケ粉末を
水乃至熱水で抽出したものであることを特徴とする
（1）記載の感染防御・治療剤、（3）マイタケ抽出物
が、生マイタケ、乾燥マイタケ若しくは/及び乾燥マイ
タケ粉末を水乃至熱水で抽出して得られる抽出液にアル
コールを加え、放置後液面若しくは液中に浮遊又は容器
の壁面に付着する物質を取除いた画分であることを特徴
とする（1）記載の感染防御・治療剤、That is, the present invention relates to (1) an agent for preventing and treating infection characterized by containing maitake extract or / and dried maitake powder, and (2) a maitake extract comprising raw maitake, dried maitake and / or (1) the agent for preventing or treating infection according to (1), wherein the dried maitake powder is extracted from water or hot water, and (3) the maitake extract is obtained from raw maitake, dried maitake or / and dried maitake powder. It is a fraction obtained by adding alcohol to an extract obtained by extraction with water or hot water and removing substances floating on the liquid surface or in the liquid after standing or adhering to the wall surface of the container (1) Infection protection / therapeutic agent as described
【０００７】（4）マイタケ抽出物が、生マイタケ、乾
燥マイタケ若しくは/及び乾燥マイタケ粉末を水乃至熱
水で抽出して得られる抽出液にアルコールを加え、放置
後液面若しくは液中に浮遊又は容器の壁面に付着する物
質を取り除いた後、更にアルコールを加えて沈殿物とし
て生じる高分子多糖体画分であることを特徴とする
（1）記載の感染防御・治療剤、（5）マイタケ抽出物
が、生マイタケ、乾燥マイタケ若しくは/及び乾燥マイ
タケ粉末を水乃至熱水で抽出して得られる抽出液にアル
コールを加え、放置後液面若しくは液中に浮遊又は容器
の壁面に付着する物質を取り除いた後、更にアルコール
を加えて沈殿物として生じる高分子多糖体画分を採取
し、ついで該画分をＤＥＡＥ−Cellulofine若しくはＤ
ＥＡＥ−Sepharoseで処理して得られる精製高分子多糖
体画分であることを特徴とする（1）記載の感染防御・
治療剤、（6）グラム陽性菌を対象とすることを特徴と
する（1）乃至（5）記載の感染防御・治療剤、(4) The maitake extract is obtained by extracting raw maitake, dried maitake or / and dried maitake powder with water or hot water, adding alcohol to the extract, leaving the suspension on the liquid surface or in the liquid after standing. The agent for preventing or treating infection according to (1), wherein the agent is a high-molecular-weight polysaccharide fraction that is formed as a precipitate by removing the substance adhering to the wall surface of the container and then further adding alcohol. (5) Maitake mushroom extraction The product is obtained by extracting raw maitake, dried maitake or / and dried maitake powder with water or hot water, and adding alcohol to the liquid.After standing, a substance floating on the liquid surface or in the liquid or adhering to the wall surface of the container is removed. After removal, alcohol was further added to collect a high-molecular-weight polysaccharide fraction formed as a precipitate, and then the fraction was subjected to DEAE-Cellulofine or D
(1) the purified polysaccharide fraction obtained by treatment with EAE-Sepharose;
Therapeutic agent, (6) the infection preventive / therapeutic agent according to (1) to (5), which is intended for gram-positive bacteria;
【０００８】（7）グラム陽性菌がリステリア菌である
ことを特徴とする請求項６記載の感染防御・治療剤、
（8）（1）乃至（5）記載のいずれかの感染防御・治療
剤と抗生物質とを含有することを特徴とする感染防御・
治療剤、（9）抗生物質がペプチド系抗生物質であるこ
とを特徴とするグラム陽性菌対象の（8）記載の感染防
御・治療剤に関する。(7) The agent according to the above (6), wherein the Gram-positive bacterium is Listeria monocytogenes.
(8) A method for preventing infection characterized by containing the agent for preventing or treating infection according to any one of (1) to (5) and an antibiotic.
The present invention relates to a therapeutic agent, (9) the protective / therapeutic agent according to (8), which is for a gram-positive bacterium, wherein the antibiotic is a peptide antibiotic.
【０００９】以下本発明について詳述する。本発明にお
ける感染防御・治療とは各種生体にとって有害な微生物
の感染（病原微生物の生体内侵入）の予防、感染後の発
症の阻止（増殖阻止）並びに発症（病的状態）の治療を
意味する。本発明における生体にとって有害な病原微生
物としては、リステリア菌、ブドウ球菌、連鎖球菌、肺
炎球菌、腸球菌、クロストリジウム属菌等のグラム陽性
菌の他、結核菌、サルモネラ属菌等細胞内寄生性細菌を
含む。又本発明に言う生体とは人間以外に家畜、ペット
動物等も包含する。Hereinafter, the present invention will be described in detail. The term “protection / treatment of infection” in the present invention means prevention of infection of microorganisms harmful to various living organisms (invasion of pathogenic microorganisms into living organisms), prevention of onset after infection (inhibition of growth), and treatment of onset (pathological condition). . Examples of pathogenic microorganisms harmful to living organisms in the present invention include Listeria monocytogenes, staphylococci, streptococci, pneumococci, enterococci, gram-positive bacteria such as Clostridium, tuberculosis bacteria, and intracellular bacteria such as Salmonella. including. The living body referred to in the present invention includes livestock, pet animals and the like in addition to humans.
【００１０】本発明における抗生物質としては、バンコ
マイシン、タゴシット、バラマイシン等ペプチド系の他
に、ペニシリン系・セフェム系・前記以外のβラクタム
系・アミノグルコシド系・マクロライド系・テトラサイ
クリン系・クロラムフェニコール系・リンコマイシン系
・ホスホマイシン系抗生物質、キノロン系・ニューキノ
ロン系薬剤等が含まれる。[0010] Antibiotics in the present invention include, in addition to peptides such as vancomycin, tagosit, and balamycin, penicillins, cephems, β-lactams, aminoglucosides, macrolides, tetracyclines, and chloram. Phenicol / lincomycin / fosfomycin antibiotics, quinolone / new quinolone drugs and the like are included.
【００１１】本発明において、マイタケは（Grifola f
rondosa)、白マイタケ（Grifola albicans）、チョレ
イマイタケ（Grifola umbellata）、トンビマイタケ
（Grifola gigantea)等いづれも用いることが出来る。
又これらマイタケ類の子実体、菌糸体いずれも用いるこ
とが出来るが、最近ではマイタケの子実体の人工栽培が
可能となり、安定した原料確保の面から該マイタケの子
実体を使用するのが好ましい。In the present invention, maitake is (Grifola f
rondosa), white maitake (Grifola albicans), choreimaitake (Grifola umbellata), and tonmaimaitake (Grifola gigantea).
Any of the fruit bodies and mycelia of these maitakes can be used, but recently, artificial cultivation of the fruit bodies of maitake has become possible, and it is preferable to use the fruit bodies of maitake from the viewpoint of securing stable raw materials.
【００１２】生マイタケは収穫後、出来るだけ新鮮なも
のを使用するのが好ましいが、食に供する状態であれば
用いることができる。使用部位は特に特定される事なく
茎部以上すべて使用しうる。乾燥マイタケとしては天
日、熱風乾燥或いは凍結乾燥したもの等いずれも用いる
ことが出来る。乾燥マイタケ粉末は粒子の粗いものから
微細なものまで使用することが出来る。[0012] It is preferable to use fresh maitake mushrooms as fresh as possible after harvesting, but any maitake mushrooms that can be used for food can be used. The site to be used can be used at all sites or more without particular limitation. Any of dried mushrooms, such as sun-dried, hot-air dried or freeze-dried, can be used. The dried maitake powder can be used from coarse to fine particles.
【００１３】抽出の方法は常温〜135℃で15分〜数時間
行う。短時間で行うには圧力下、100℃以上、例えば圧
力を用いて1〜2気圧下120℃前後で30分〜1時間前後抽出
を行う。水としては蒸留水、イオン交換水、水道水、天
然水いずれも使用しうる。乾燥マイタケ若しくは乾燥マ
イタケ粉1重量に対して水を4倍容量以上適宜使用する。
生マイタケを使用する場合は1重量に対して2倍容量以上
適宜使用する。以上の様に水乃至熱水抽出液はそのま
ま、更に濃縮して濃縮エキス若しくは濃縮エキスを乾燥
して使用することが出来る。The extraction is carried out at normal temperature to 135 ° C. for 15 minutes to several hours. To perform the reaction in a short time, extraction is performed at a pressure of 100 ° C. or more, for example, at a pressure of 1 to 2 at 120 ° C. for 30 minutes to 1 hour. As the water, any of distilled water, ion exchange water, tap water and natural water can be used. Water is appropriately used in an amount of at least 4 times the volume of dried Maitake or dry Maitake powder.
When using raw maitake, use more than twice the volume per weight. As described above, the water or hot water extract can be further concentrated as it is, and the concentrated extract or the concentrated extract can be dried and used.
【００１４】水乃至熱水抽出液はアルコール沈殿法によ
り精製することが可能である。例えばアルコールを抽出
液に加え沈殿する物質を採取する。沈殿物はマイタケ中
に含まれる高分子多糖体β-グルカンを主体にした画分
であり、例えばアルコールを比較的低濃度（20〜70容量
％更に好ましくは30〜60容量％）加えた段階で一定時間
静置し生ずる液面、液中に浮遊する物質或いは容器の壁
に付着する物資を除去し、更にアルコールを70容量％以
上になるよう加え、沈殿する物質を採取する様な手段を
とることにより精製が可能となる。The water or hot water extract can be purified by an alcohol precipitation method. For example, alcohol is added to the extract, and a substance that precipitates is collected. The precipitate is a fraction mainly composed of the high-molecular-weight polysaccharide β-glucan contained in maitake, for example, at a stage where alcohol is added at a relatively low concentration (20 to 70% by volume, more preferably 30 to 60% by volume). Remove the liquid surface, substances floating in the liquid or substances adhering to the walls of the container after standing for a certain period of time, add alcohol to 70% by volume or more, and take measures to collect the precipitated substances. This allows for purification.
【００１５】以上のように得られた沈殿物は水に可溶で
水溶液とし上述の様にアルコール沈殿法を繰り返す事に
より更に精製することも出来る。こうして得られた高分
子多糖体画分は、次のような性質を有する。 外観： 褐色色調の吸湿性の粉末 溶解性： 水、アルカリ溶液に可溶 呈色反応： アンスロン反応及びニンヒドリン反応陽性 水溶液の液性：中性〜弱酸性The precipitate obtained as described above is soluble in water, made into an aqueous solution, and can be further purified by repeating the alcohol precipitation method as described above. The high molecular polysaccharide fraction thus obtained has the following properties. Appearance: Brown-colored hygroscopic powder Solubility: Soluble in water and alkaline solutions Coloring reaction: Positive anthrone reaction and ninhydrin reaction Liquidity of aqueous solution: Neutral to weakly acidic
【００１６】又高分子多糖体画分は、更にクロマトグラ
フイー、ゲル濾過等により、精製することも可能であ
る。例えば DEAE-Cellulofine、DEAE-Sepharose等使用
することが出来る。The high molecular polysaccharide fraction can be further purified by chromatography, gel filtration and the like. For example, DEAE-Cellulofine, DEAE-Sepharose and the like can be used.
【００１７】本発明のマイタケ抽出物は、リステリア菌
感染マウスに単独、若しくはバンコマイシン（ＶＣＭ）
との併用投与を行い、ＶＣＭ単独に比べ該菌に対する殺
傷効果の増強が認められたが、これは、マイタケ抽出物
が、各種免疫細胞そのものを賦活化させるためと見ら
れ、特に免疫力の低下した高齢者、癌患者、糖尿病患者
の感染症予防・治療に有効である。又、マイタケ抽出物
とＶＣＭとの併用では、リステリア菌によって起こる髄
膜脳炎、敗血症等リステリア症、ＶＣＭの適応であるＭ
ＲＳＡ（メチシリン耐性黄色ブドウ球菌）による感染症
あるいは骨髄移植時の消化管内殺菌にもより有効性が期
待できる。The maitake extract of the present invention can be administered to mice infected with Listeria monocytogenes alone or by vancomycin (VCM).
, The killing effect against the bacterium was enhanced compared to VCM alone. This is thought to be due to the fact that the maitake extract activates various immune cells themselves. It is effective for the prevention and treatment of infectious diseases of elderly people, cancer patients and diabetes patients. In addition, in combination with the maitake extract and VCM, meningoencephalitis caused by Listeria monocytogenes, listeriosis such as sepsis, M
It is also expected to be more effective for infections caused by RSA (methicillin-resistant Staphylococcus aureus) or for sterilization of the digestive tract during bone marrow transplantation.
【００１８】以上の様に本発明のマイタケ由来の感染防
御・治療剤は、現在の臨床現場において、要求度の高い
感染症の予防や治療に効果があり、例えばカプセル剤、
錠剤、散剤、シロップ剤等種々の形態の剤形で、単独で
或いは抗生物質との併用で使用することが出来る。又マ
イタケ由来の感染防御・治療剤と抗生物質との併用の一
形態として、合剤による投与形態もある。例えばカプセ
ル、錠剤、散剤、シロップ剤、液剤とすることが出来、
合剤とする抗生物質の性質に合わせ適宜剤形を選択する
ことが出来る。As described above, the agent for preventing or treating infection of Maitake mushrooms of the present invention is effective in the prevention and treatment of highly demanded infectious diseases in the current clinical practice.
Various forms such as tablets, powders and syrups can be used alone or in combination with antibiotics. As one form of the combination use of an agent for protection and treatment of infection from Maitake mushroom and an antibiotic, there is also a form of administration using a combination drug. For example, capsules, tablets, powders, syrups, liquids,
The dosage form can be appropriately selected according to the properties of the antibiotic to be combined.
【００１９】[0019]
【発明の実施の形態】［実施例１］ 製造方法 （１）乾燥マイタケ粉末 人工栽培で作った生マイタケ子実体の枝部、傘部を乾燥
室の棚に並べ最初は約６０℃から段階的に温度を上げて
８０℃でほぼ１日かけて乾燥した。ついで乾燥マイタケ
を製粉機で粉砕し微粉末を得た。DESCRIPTION OF THE PREFERRED EMBODIMENTS [Example 1] Manufacturing method (1) Dried maitake powder Branches and umbrellas of raw maitake fruit bodies produced by artificial cultivation are arranged on shelves in a drying room, and are initially stepped from about 60 ° C. And dried at 80 ° C. for approximately one day. Subsequently, the dried Maitake was crushed with a mill to obtain a fine powder.
【００２０】（２）マイタケ抽出分画 乾燥マイタケ子実体の粉末300ｇをイオン交換水2700ml
で加圧下115〜120℃で約1時間処理し、その後濾過して
黒褐色液約1600mlを得る。該溶液を減圧下約500ml程度
まで濃縮し室温で、エタノール500mlを加え、10℃以下
で3〜10時間放置すると液面、液中に浮遊及び容器の壁
面に付着する茶褐色の物質が生成した。これら物質を除
去し、褐色の溶液を得る。(2) Extraction and fractionation of maitake mushrooms 300 g of dried maitake fruit body powder was added to 2700 ml of deionized water.
For about 1 hour at 115-120 ° C. under pressure, and then filtered to obtain about 1600 ml of a dark brown liquid. The solution was concentrated under reduced pressure to about 500 ml, and at room temperature, 500 ml of ethanol was added, and the mixture was allowed to stand at 10 ° C. or lower for 3 to 10 hours to produce a brown substance floating on the liquid surface, floating in the liquid and adhering to the wall surface of the container. Removal of these materials gives a brown solution.
【００２１】ｉ 上記褐色の液約400mlを減圧下アル
コールを除去し、更に濃縮してBrix値50の濃縮液を得
た。該濃縮液を回転円盤式スプレードライ装置を用いて
噴霧乾燥して褐色乾燥粉末25gを得た。 ii 上記褐色の溶液約400ｍｌに更にアルコール600ml
加え沈殿析出する褐色の物質、高分子多糖体画分20gを
得た。 iii 上記iiで得られた高分子多糖体画分0.5ｇをDEAE-
Cellulofineで処理して褐色の精製高分子多糖体画分
（分子量100万〜120万）0.3ｇを得た。I About 400 ml of the above brown liquid was removed of alcohol under reduced pressure, and further concentrated to obtain a concentrated liquid having a Brix value of 50. The concentrated liquid was spray-dried using a rotating disk type spray-drying apparatus to obtain 25 g of a brown dry powder. ii About 400 ml of the above brown solution and 600 ml of alcohol
In addition, 20 g of a brown substance which precipitates and precipitates, a high molecular polysaccharide fraction was obtained. iii 0.5 g of the high molecular weight polysaccharide fraction obtained in
By treating with Cellulofine, 0.3 g of a brown purified high-molecular-weight polysaccharide fraction (molecular weight: 1,000,000 to 1.2 million) was obtained.
【００２２】［実施例２］ 感染実験 （１）試験方法 ICR雄性マウス（6週齢）10匹を1群として、上記方法で
製造した精製高分子多糖体画分単独投与群、精製高分子
多糖体画分とバンコマイシン（VCM）との併用投与群、V
CM単独投与群及び対照群（非投与群）の4群による感染
投与試験を行った。精製高分子多糖体画分とVCMの併用
群では、精製高分子多糖体画分（10mg/kg）を隔日3回腹
腔内投与し、投与開始後10日目にリステリア菌（Lister
ia monocytogenes）を感染させ、24時間後にVCM(10mg/
kg)を投与した。他の群については、被験物以外は同様
方法で行った。10日間の感染マウスの生存率の変動と、
感染開始後3日目のマウス腹腔内及びマクロファージ内
でのリステリア菌の生存率、その時採取したマクロファ
ージのIL-1量を測定し、精製高分子多糖体画分単独投与
群及びVCM単独投与群と比較した。更に感染開始6日目の
マウスから全脾臓細胞とT細胞を調整し、各々のリステ
リア菌殺傷活性能を調べた。Example 2 Infection Experiment (1) Test Method A group of 10 ICR male mice (6 weeks of age) was used as a group, and the purified polymer polysaccharide fraction alone administered group, purified polymer polysaccharide was administered. V-combination group with body fraction and vancomycin (VCM)
An infection administration test was performed using four groups, a CM alone administration group and a control group (non-administration group). In the combination group of purified polysaccharide fraction and VCM, the purified polysaccharide fraction (10 mg / kg) was intraperitoneally administered three times every other day, and 10 days after the start of administration, Listeria monocytogenes (Lister
ia monocytogenes), and 24 hours later, VCM (10 mg /
kg). Other groups were performed in the same manner except for the test substance. The change in the survival rate of infected mice for 10 days,
The survival rate of Listeria monocytogenes in the mouse intraperitoneal cavity and macrophages on day 3 after the start of infection, the amount of IL-1 in the macrophages collected at that time was measured, and the purified polymer polysaccharide fraction alone administration group and the VCM alone administration group were compared. Compared. Further, total spleen cells and T cells were prepared from the mice 6 days after the start of infection, and their Listeria monocytogenes killing activity was examined.
【００２３】（２）試験結果 対照群で感染3日目で全マウスが死亡したのに対して、
精製高分子多糖体画分単独投与や、精製高分子多糖体画
分とVCM併用群では10日後でも半数のマウスに生存が認
められた。マウス腹腔内でのリステリア菌の生存率は精
製高分子多糖体画分とVCM併用群において最も減少し
た。更にマクロファージのIL-1の産生能は精製高分子多
糖体画分によって対照群に比べ2.8倍に増加した。しか
しこの産生能はVCMでは妨害されなかった。全脾臓細胞
ではリステリア菌の生存菌数はVCM単独投与群が対照群
の46％であったのに対し、精製高分子多糖体画分単独又
はVCM併用によって34〜19％まで減少した。一方、高分
子多糖体画分単独投与ではＴ細胞はこの精製高分子多糖
体画分によって活性化され、対照群の1.3倍程度の殺傷
効果を示した。これはT細胞が精製高分子多糖体画分に
よって活性化され、リステリア菌抗原特異的な傷害作用
を獲得した結果と考えられた。なおVCMとの併用によっ
てその効果は2.6倍まで増加した。以上は精製高分子多
糖体画分の試験結果であるが、上記〔実施例1〕（１）i
の抽出物、ii で製造した高分子多糖体画分についても
効果の差異はあるものの、同様の効果が認められた。(2) Test results In the control group, all mice died on the third day of infection,
In the group administered with the purified high-molecular-weight polysaccharide fraction alone or in the combined group with the purified high-molecular-weight polysaccharide fraction and VCM, half of the mice survived even after 10 days. The viability of Listeria monocytogenes in the mouse intraperitoneal cavity decreased most in the combined group of purified polysaccharide fraction and VCM. Furthermore, the ability of macrophages to produce IL-1 was increased 2.8-fold by the purified high-molecular-weight polysaccharide fraction compared to the control group. However, this productivity was not disturbed by VCM. In all spleen cells, the viable cell count of Listeria monocytogenes was reduced to 34 to 19% by the purified high-molecular-weight polysaccharide fraction alone or in combination with the VCM, while the group to which VCM was administered alone was 46% of the control group. On the other hand, when the high-molecular-weight polysaccharide fraction was administered alone, T cells were activated by this purified high-molecular-weight polysaccharide fraction, and showed a killing effect about 1.3 times that of the control group. This was thought to be because T cells were activated by the purified high-molecular-weight polysaccharide fraction and acquired a Listeria monocytogenes antigen-specific damaging effect. The effect was increased to 2.6 times by the combination with VCM. The above are the test results of the purified high-molecular-weight polysaccharide fraction. The above [Example 1] (1) i
The same effect was observed for the extract of No. 1 and the high-molecular-weight polysaccharide fraction prepared in No. ii, although there were differences in the effects.
【００２４】[0024]
【発明の効果】本発明により、生体にとって有害な病原
微生物に対する感染防御能を高め、病原微生物の感染を
予防し、感染してもその発症を阻止、発症しても治療を
容易にすることができる。又耐性を生じやすい抗生物質
・化学療法剤の使用を極力減少させ、耐性菌の出現を防
止することができる。Industrial Applicability According to the present invention, the ability to protect against pathogenic microorganisms harmful to living organisms can be enhanced, the infection of pathogenic microorganisms can be prevented, the onset of infection can be prevented, and the treatment can be facilitated. it can. In addition, the use of antibiotics and chemotherapeutic agents that easily cause resistance can be reduced as much as possible, and the emergence of resistant bacteria can be prevented.
Claims (9)
タケ粉末を含有することを特徴とする感染防御・治療
剤。1. An agent for preventing and treating infection, comprising a maitake extract and / or a dried maitake powder.
イタケ若しくは/及び乾燥マイタケ粉末を水乃至熱水で
抽出したものであることを特徴とする請求項1記載の感
染防御・治療剤。2. The method according to claim 1, wherein the maitake extract is obtained by extracting raw maitake, dried maitake, and / or dried maitake powder with water or hot water.
イタケ若しくは/及び乾燥マイタケ粉末を水乃至熱水で
抽出して得られる抽出液にアルコールを加え、放置後液
面若しくは液中に浮遊又は容器の壁面に付着する物質を
取除いた画分であることを特徴とする請求項1記載の感
染防御・治療剤。3. The maitake extract is obtained by extracting raw maitake, dried maitake or / and dried maitake powder with water or hot water, adding alcohol to the extract, and floating or floating on the liquid surface or in the liquid after standing. 2. The infection preventive / therapeutic agent according to claim 1, wherein the fraction is a fraction from which a substance attached to a wall surface of the is removed.
イタケ若しくは/及び乾燥マイタケ粉末を水乃至熱水で
抽出して得られる抽出液にアルコールを加え、放置後液
面若しくは液中に浮遊又は容器の壁面に付着する物質を
取り除いた後、更にアルコールを加えて沈殿物として生
じる高分子多糖体画分であることを特徴とする請求項1
記載の感染防御・治療剤。4. The maitake extract is obtained by extracting raw maitake, dried maitake or / and dried maitake powder with water or hot water, adding alcohol to the extract, floating on the liquid surface or in the liquid after standing, or in a container. 2. A high-molecular-weight polysaccharide fraction produced as a precipitate by removing a substance adhering to the wall surface of the mixture and further adding alcohol.
The preventive or therapeutic agent for infection described in the above.
イタケ若しくは/及び乾燥マイタケ粉末を水乃至熱水で
抽出して得られる抽出液にアルコールを加え、放置後液
面若しくは液中に浮遊又は容器の壁面に付着する物質を
取り除いた後、更にアルコールを加えて沈殿物として生
じる高分子多糖体画分を採取し、ついで該画分をＤＥＡ
Ｅ−Cellulofine若しくはＤＥＡＥ−Sepharoseで処理し
て得られる精製高分子多糖体画分であることを特徴とす
る請求項1記載の感染防御・治療剤。5. The maitake extract is obtained by extracting raw maitake, dried maitake or / and dried maitake powder with water or hot water, adding alcohol to the extract, floating on the liquid surface or in the liquid after standing, or in a container. After removing the substance adhering to the wall surface of the above, the alcohol was further added to collect the high-molecular-weight polysaccharide fraction generated as a precipitate, and then the fraction was subjected to DEA.
2. The agent according to claim 1, which is a purified high-molecular-weight polysaccharide fraction obtained by treating with E-Cellulofine or DEAE-Sepharose.
する請求項1乃至5記載の感染防御・治療剤。6. The method according to claim 1, wherein the agent is a gram-positive bacterium.
を特徴とする請求項６記載の感染防御・治療剤。7. The agent according to claim 6, wherein the gram-positive bacterium is Listeria monocytogenes.
・治療剤と抗生物質とを含有することを特徴とする感染
防御・治療剤。8. An infection-protecting / therapeutic agent comprising the infection-protecting / therapeutic agent according to any one of claims 1 to 5 and an antibiotic.
とを特徴とするグラム陽性菌対象の請求項8記載の感染
防御・治療剤。9. The method according to claim 8, wherein the antibiotic is a peptide antibiotic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24919299A JP4726274B2 (en) | 1999-09-02 | 1999-09-02 | Maitake-derived infection prevention and treatment agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24919299A JP4726274B2 (en) | 1999-09-02 | 1999-09-02 | Maitake-derived infection prevention and treatment agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001072601A true JP2001072601A (en) | 2001-03-21 |
| JP2001072601A5 JP2001072601A5 (en) | 2006-10-05 |
| JP4726274B2 JP4726274B2 (en) | 2011-07-20 |
Family
ID=17189280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24919299A Expired - Fee Related JP4726274B2 (en) | 1999-09-02 | 1999-09-02 | Maitake-derived infection prevention and treatment agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4726274B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001172194A (en) * | 1999-12-17 | 2001-06-26 | Yukiguni Maitake Co Ltd | Nitrogen monoxide (no)-production inducer originating from grifola frondosa (a kind of mushroom) |
| JP2006131503A (en) * | 2003-04-08 | 2006-05-25 | Nippon Zettoc Co Ltd | Photo aging-preventing agent and photo aging-improving agent |
| JP2012180329A (en) * | 2011-03-02 | 2012-09-20 | Hokkaido Univ | Promoter for production and secretion of antimicrobial substance |
| CN103724445A (en) * | 2013-12-25 | 2014-04-16 | 广东省微生物研究所 | Preparation method and blood sugar lowering function of Grifola frondosa polysaccharide F2 |
| JP2014080373A (en) * | 2012-10-12 | 2014-05-08 | Yukiguni Maitake Co Ltd | Herpes simplex virus infection preventive/therapeutic agent from grifola frondosa extract |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04308531A (en) * | 1991-04-04 | 1992-10-30 | Koru Media Japan Kk | Therapeutic agent for retrovirus infection containing sulfated beta-glucan having anti-aids virus activity |
-
1999
- 1999-09-02 JP JP24919299A patent/JP4726274B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04308531A (en) * | 1991-04-04 | 1992-10-30 | Koru Media Japan Kk | Therapeutic agent for retrovirus infection containing sulfated beta-glucan having anti-aids virus activity |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001172194A (en) * | 1999-12-17 | 2001-06-26 | Yukiguni Maitake Co Ltd | Nitrogen monoxide (no)-production inducer originating from grifola frondosa (a kind of mushroom) |
| JP2006131503A (en) * | 2003-04-08 | 2006-05-25 | Nippon Zettoc Co Ltd | Photo aging-preventing agent and photo aging-improving agent |
| JP2012180329A (en) * | 2011-03-02 | 2012-09-20 | Hokkaido Univ | Promoter for production and secretion of antimicrobial substance |
| JP2014080373A (en) * | 2012-10-12 | 2014-05-08 | Yukiguni Maitake Co Ltd | Herpes simplex virus infection preventive/therapeutic agent from grifola frondosa extract |
| CN103724445A (en) * | 2013-12-25 | 2014-04-16 | 广东省微生物研究所 | Preparation method and blood sugar lowering function of Grifola frondosa polysaccharide F2 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4726274B2 (en) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2532392T3 (en) | Antimicrobial peptides | |
| KR101761578B1 (en) | Novel enteropathogenic Escherichia coli bacteriophage Esc-CHP-2 and its use for preventing proliferation of enteropathogenic Escherichia coli | |
| JP2001523723A (en) | Phospholipids with antimicrobial activity in the presence or absence of antimicrobial agents | |
| JP5088911B2 (en) | Antimicrobial substance production / secretion promoter | |
| JP2013522315A (en) | Method of using Bacillus subtilis strains for the prevention and treatment of gastrointestinal conditions | |
| US20200171077A1 (en) | Compositions and methods for treating and preventing bacterial infections | |
| CN114989254A (en) | Polypeptide, design method thereof and application of polypeptide in preparation of fusobacterium nucleatum inhibiting product or colorectal cancer preventing medicine | |
| KR20180000531A (en) | Antimicrobial peptides with high synergistic effect with antibiotics against multidrug resistant gram-negative bacteria and their uses | |
| CN110612349A (en) | Novel pseudomonas aeruginosa bacteriophage Pse-AEP-3 and use thereof for inhibiting proliferation of pseudomonas aeruginosa | |
| RU2628312C2 (en) | Antibacterial composition for prevention or treatment of hospital infections (versions), bacteriophage stamps used to obtain such composition | |
| Bhuvaneswari et al. | Antibacterial activity of spirulina (Arthospira platensis geitler) against bacterial pathogens in Aquaculture | |
| JP2001072601A (en) | Infection preventing and treating agent derived from grifola frondosa | |
| CN101443352A (en) | Novel analogues of antimicrobial and anticancer peptide synthesized and produced from Gaegurin 5 | |
| CN116120419A (en) | Novel antibacterial peptide and application thereof | |
| KR101689033B1 (en) | Bacteriophage that kills Propionibacterium acnes | |
| KR20080069735A (en) | A antibacterial composition comprising an extract of ulva lactuca | |
| WO2016066784A1 (en) | Cyclic antimicrobial pseudopeptides and uses thereof | |
| JP2006282634A (en) | Preventing or treating agent for systemic inflammation response syndrome | |
| KR102275801B1 (en) | Composition comprising cis-jasmone for inhibiting the formation of biofilm | |
| KR101686428B1 (en) | An anti-microbial peptide, Periplanetasin-2 isolated from Periplaneta americana and its synthetic composition | |
| CN110354078B (en) | Anti-candida albicans composition containing nisin and preparation method thereof | |
| JP2005082806A (en) | Fucoidan originating from cladosiphon okamuranus and immunostimulator | |
| CN111150835A (en) | Application of porcine β -defensin 2 peptide fragment in preparation of pharmaceutical composition for preventing and treating streptococcus suis infection | |
| CN101415725B (en) | Peptide compound with biological activity, its preparation and its application | |
| JP4542644B2 (en) | Method for enhancing antibacterial action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060823 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060823 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100309 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100507 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110315 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110412 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140422 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |